1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Cervical Dysplasia - Pipeline Review, H2 2014

Cervical Dysplasia - Pipeline Review, H2 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 66 pages

Cervical Dysplasia - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Cervical Dysplasia - Pipeline Review, H2 2014’, provides an overview of the Cervical Dysplasia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cervical Dysplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Dysplasia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cervical Dysplasia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Cervical Dysplasia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Cervical Dysplasia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cervical Dysplasia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cervical Dysplasia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cervical Dysplasia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Cervical Dysplasia - Pipeline Review, H2 2014
Table of Contents
Introduction 5
Global Markets Direct Report Coverage 5
Cervical Dysplasia Overview 6
Therapeutics Development 7
Pipeline Products for Cervical Dysplasia - Overview 7
Pipeline Products for Cervical Dysplasia - Comparative Analysis 8
Cervical Dysplasia - Therapeutics under Development by Companies 9
Cervical Dysplasia - Therapeutics under Investigation by Universities/Institutes 10
Cervical Dysplasia - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Cervical Dysplasia - Products under Development by Companies 13
Cervical Dysplasia - Products under Investigation by Universities/Institutes 14
Cervical Dysplasia - Companies Involved in Therapeutics Development 15
CEL-SCI Corporation 15
Helix BioPharma Corp. 16
Inovio Pharmaceuticals, Inc. 17
PDS Biotechnology Corporation 18
VLPbio 19
Cervical Dysplasia - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
CerviVax - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
CIGB-228 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
interferon alpha-2b (recombinant) - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Leukocyte Interleukin - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
PDS-0101 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Vaccine for Cervical Intraepithelial Neoplasia - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
VGX-3100 - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Cervical Dysplasia - Recent Pipeline Updates 40
Cervical Dysplasia - Dormant Projects 53
Cervical Dysplasia - Discontinued Products 54
Cervical Dysplasia - Product Development Milestones 55
Featured News and Press Releases 55
Jul 23, 2014: Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 55
Jun 11, 2014: Inovio Pharmaceuticals Clarifies Facts of its VGX-3100 Phase II Trial and Immunotherapy Technology 56
Feb 11, 2014: PDS Biotechnology Announces Treatment of First Patient with PDS0101 based on the Novel Versamune Cancer Immunotherapy Platform in a Phase 1 Clinical Trial 57
Oct 10, 2012: Inovio Pharma's DNA-based Therapeutic Cancer Vaccine Produces Immune Responses To Kill Target Cells In Phase I Study 57
May 01, 2012: Inovio Receives US Patent Protection For Synthetic Vaccine For Cervical Dysplasia And Cancer 59
Nov 11, 2011: FDA Removes Clinical Hold For Helix's Topical Interferon Alpha-2b Phase II/III Efficacy Trial IND Application 59
Oct 31, 2011: Fierce Vaccines Highlights Inovio's Cervical Dysplasia And Cancer Vaccine As One Of 10 Promising Therapeutic Vaccines 60
Oct 05, 2011: Inovio's Synthetic Vaccine For Cancer Recognized As Most Promising Research At Global Vaccine Congress 61
Jul 15, 2011: Inovio Demonstrates T Cell Immune Response From Therapeutic Cervical Dysplasia And Cancer DNA Vaccine 62
May 09, 2011: Inovio Reports Long-Term Immune Responses From Therapeutic Cervical Dysplasia And Cancer DNA Vaccine 63
Appendix 65
Methodology 65
Coverage 65
Secondary Research 65
Primary Research 65
Expert Panel Validation 65
Contact Us 66
Disclaimer 66

List of Tables

Number of Products under Development for Cervical Dysplasia, H2 2014 7
Number of Products under Development for Cervical Dysplasia - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Products under Investigation by Universities/Institutes, H2 2014 14
Cervical Dysplasia - Pipeline by CEL-SCI Corporation, H2 2014 15
Cervical Dysplasia - Pipeline by Helix BioPharma Corp., H2 2014 16
Cervical Dysplasia - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014 17
Cervical Dysplasia - Pipeline by PDS Biotechnology Corporation, H2 2014 18
Cervical Dysplasia - Pipeline by VLPbio, H2 2014 19
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Stage and Target, H2 2014 22
Number of Products by Stage and Mechanism of Action, H2 2014 24
Number of Products by Stage and Route of Administration, H2 2014 26
Number of Products by Stage and Molecule Type, H2 2014 28
Cervical Dysplasia Therapeutics - Recent Pipeline Updates, H2 2014 40
Cervical Dysplasia - Dormant Projects, H2 2014 53
Cervical Dysplasia - Discontinued Products, H2 2014 54

List of Figures

Number of Products under Development for Cervical Dysplasia, H2 2014 7
Number of Products under Development for Cervical Dysplasia - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 11
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Top 10 Targets, H2 2014 21
Number of Products by Stage and Top 10 Targets, H2 2014 21
Number of Products by Top 10 Mechanism of Actions, H2 2014 23
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 23
Number of Products by Top 10 Routes of Administration, H2 2014 25
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 25
Number of Products by Top 10 Molecule Types, H2 2014 27
Number of Products by Stage and Top 10 Molecule Types, H2 2014 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Proteinuria Treatment Market: By Type (Angiotensin Converting Enzyme (ACE) Inhibitors, Aldosterone Antagonist (i.e., spironolactone), Angiotensin Receptor Blocker (ARB), and Others) & By Region-Forecast (2016-2021)

Proteinuria Treatment Market: By Type (Angiotensin Converting Enzyme (ACE) Inhibitors, Aldosterone Antagonist (i.e., spironolactone), Angiotensin Receptor Blocker (ARB), and Others) & By Region-Forecast (2016-2021)

  • $ 5250
  • Industry report
  • August 2016
  • by Industry ARC

Proteinuria is a result of an excess of serum proteins in the urine, which can led to renal damage. The most common cause of proteinuria is diabetes. Globally, development the arena of proteomics and ...

Benign prostatic hyperplasia (BPH)- Market Insights, Epidemiology and Market Forecast-2023

Benign prostatic hyperplasia (BPH)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Benign prostatic hyperplasia (BPH) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of ...

Endometriosis- Market Insights, Epidemiology and Market Forecast-2023

Endometriosis- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Endometriosis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...

Global Endometriosis Industry

October 2016 $ 4950

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.